tolebrutinib
sanofi
['tolebrutinib', 'sanofi']
a long-term extension study of a phase 2b trial demonstrated that treatment with #tolebrutinib 60 mg/day for 2.5 years was safe for patients with relapsing #ms, with no new signals observed. #aan2023 read: 
Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments